Matuzumab
Based on 1 Customer Validation
Matuzumab (EMD 72000) is a humanized anti-EGFR monoclonal antibody that blocks EGFR activation and downstream signaling, inhibits tumor growth. Deglycosylation and the possible elimination of ADCC activity can reduce the in vivo anti-tumor activity of Mattuzumab.
For research use only. We do not sell to patients.
- Purity : 99.50%
- CAS No.: 339186-68-4
- Molecular Weight:145.5 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All EGFR Isoforms
More
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
ERBB1/EGFR/HER1
In Vitro
Matuzumab (10 ng, 4-72 h) can exert a powerful anti-tumor ADCC effect in the target monolayer cells of head and neck squamous cell carcinoma (SCCHN)[2].
Matuzumab was enzymatically de-glycosylated to eliminate its ADCC activity, but the de-glycosylated antibody maintained its ability to bind to A431 tumor cells, block EGFR signaling, and inhibit growth in vitro[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:UM-SCC 14C, UDSCC 4, MCF-7, UM-SCC 11B and 22B
-
Concentration:10 ng
-
Incubation Time:4, 24 or 72 h
-
Result:The increase of effector:target ratios caused enhanced tumour cell killing.
Led to a significant enhancement of effector cell activity and increased ADCC.
In Vivo
Matuzumab achieves complete remission in 87% of lung cancer xenografts and 83% of gastric cancer xenografts. The growth of drug-resistant pancreatic cancer xenograft tumors decreases by 31%[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 nd
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Human EGFR Protein (ECD, His Tag) can bind Matuzumab. The EC50 for this effect is 1.802 ng/mL. -
Flow Cytometry analysis of A431 cells labelling ERBB1/EGFR/HER1 (red) with Matuzumab (anti-ERBB1/EGFR/HER1) (HY-P9969). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
Chemical Information
-
CAS No. 339186-68-4
-
Appearance Liquid
-
Molecular Weight 145.5 kDa
-
Color Colorless to light yellow
-
SMILES
[Matuzumab]
-
Synonyms
EMD 72000
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Joan H Schiller. Developments in epidermal growth factor receptor-targeting therapy for solid tumors: focus on matuzumab (EMD 72000). Cancer Invest. 2008 Feb;26(1):81-95. [Content Brief]
[2]. Bier H, et al. Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck. Cancer Immunol Immunother. 1998 May;46(3):167-73. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Matuzumab Related Classifications
HY-P9969 Related Classifications
Powered by Bioz